Asuka Sugai

Yamagata, 9909585, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.

Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.

Journal: International journal of molecular sciences

Published: June 08, 2026

Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax.

Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax.

Journal: Anticancer research

Published: August 05, 2025

Efficient Inhibition of FOXM1 Expression and Viability of High-grade Meningioma Cells by Domatinostat-mediated Dual Targeting of HDAC1 and HDAC2.

Efficient Inhibition of FOXM1 Expression and Viability of High-grade Meningioma Cells by Domatinostat-mediated Dual Targeting of HDAC1 and HDAC2.

Journal: Anticancer research

Published: July 28, 2025

HDAC Class I Inhibitor Domatinostat Induces Apoptosis Preferentially in Glioma Stem Cells Through p53-Dependent and -Independent Activation of BAX Expression.

HDAC Class I Inhibitor Domatinostat Induces Apoptosis Preferentially in Glioma Stem Cells Through p53-Dependent and -Independent Activation of BAX Expression.

Journal: International journal of molecular sciences

Published: July 03, 2025

The MDM4 Inhibitor CEP-1347 Activates Wild-type p53 in Ovarian Clear Cell Carcinoma Cells and Potently Inhibits their Growth.

The MDM4 Inhibitor CEP-1347 Activates Wild-type p53 in Ovarian Clear Cell Carcinoma Cells and Potently Inhibits their Growth.

Journal: Anticancer research

Published: June 26, 2025

Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells.

Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells.

Journal: International journal of molecular sciences

Published: June 09, 2025

Effective Targeting of Glioma Stem Cells by BSJ-04-122, a Novel Covalent MKK4/7 Dual Inhibitor.

Effective Targeting of Glioma Stem Cells by BSJ-04-122, a Novel Covalent MKK4/7 Dual Inhibitor.

Journal: Anticancer research

Published: May 26, 2025

CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells.

CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells.

Journal: International journal of molecular sciences

Published: July 12, 2024

The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.

The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.

Journal: International journal of molecular sciences

Published: February 19, 2024

CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.

CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.

Journal: Cancers

Published: November 16, 2023

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells.

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells.

Journal: Cancers

Published: July 10, 2023

Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.

Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.

Journal: International journal of molecular sciences

Published: May 29, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026